Suzuki, Sayo

写真a

Affiliation

Faculty of Pharmacy, Department of Pharmacy 医療薬学・社会連携センター 医療薬学部門 (Shiba-Kyoritsu)

Position

Professor

Career 【 Display / hide

  • 2020.04
    -
    Present

    Keio University, Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Professor

  • 2017.04
    -
    2020.03

    Keio University, Division of Pharmaceutical Care Sciences, Faculty of Pharmacy, Associate Professor

  • 2010.01
    -
    2017.03

    慶應義塾大学, 薬学部医療薬学センター, 専任講師

  • 2009.04
    -
    2009.12

    慶應義塾大学, 医学部臨床薬剤学講座, 助教

  • 2007.04
    -
    2009.03

    慶應義塾大学, 医学部薬剤部, 助教

display all >>

Academic Background 【 Display / hide

  •  

    Kyoto University, 薬学研究科

    Graduate School, Completed, Master's course

  •  

    Kyoto University, 薬学部, 薬学科

    University, Graduated

Academic Degrees 【 Display / hide

  • 薬学修士, 京都大学, Coursework

    ラットにおけるCisplatinの腎排泄挙動と毒性

  • 博士(医学), Keio University, Dissertation, 2013.10

    S100A10 protein expression is associated with oxaliplatin sensitivity in human colorectal cancer cells.

Licenses and Qualifications 【 Display / hide

  • 日本医学教育学会認定医学教育専門家, 2023.01

  • 薬剤師免許, 1989

  • 高等学校教諭二級普通免許(理科), 1989

  • 高等学校教諭専修免許(理科), 1991

 

Research Areas 【 Display / hide

  • Life Science / Clinical pharmacy (Clinical Pharmacology)

  • Medical Education / Pharmaceutical Education

Research Keywords 【 Display / hide

  • Personalized Medicine

  • 医学・薬学教育

  • Medical professionalism

 

Books 【 Display / hide

  • 新スタンダード薬学シリーズ 第2巻 社会と薬学

    鈴木 小夜., 東京化学同人, 東京, 2024.03

    Scope: 第1章 1・4・1 プロフェッショナルとは,  Contact page: 30-33

  • 今日の臨床サポート 改訂第5版

    清宮 啓介, 鈴木 小夜, エルゼビア・ジャパン株式会社, 2024.02

    Scope: 小児薬用量の考え方と小児薬物療法における注意点(小児科)

  • 今日の臨床サポート 改訂第5版

    西村 あや子, 鈴木 小夜., エルゼビア・ジャパン株式会社, 2024.01

    Scope: 授乳婦への薬物投与

  • 今日の治療指針 2024年度版

    谷川原祐介,鈴木 小夜. , 医学書院,東京 , 2024.01

    Scope: 薬物治療モニタリング(TDM)

  • Epidemiology and Biostatistics. An Introduction to Clinical Research, Second Edition.

    Minako Matsumoto, Suzuki Sayo, Hiroshi Ochiumi., Springer, 2023.06

    Original author: Kestenbaum Bryan

display all >>

Papers 【 Display / hide

  • Drug repositioning study on the antiemetic efficacy of anamorelin for cisplatin-induced nausea and vomiting in rats.

    Nishino Haruto, Kawazoe Hitoshi, Sekiguchi Mayu, Jibiki Aya, Yokoyama Yuta, Suzuki Sayo, Nakamura Tomonori.

    BPB Reports 7 ( 1 ) 1 - 6 2024.01

    Joint Work, Accepted

  • Patient prognosis and prediction model for taking Kampo formulas in dysmenorrhea: An observational study.

    Maeda-Minami, Ayako, Kawamoto Ayako, Yoshino Tetsuhiro, Yokoyama Yuta, Suzuki Sayo , Horiba Yuko, Nakamura Tomonor, Mimura Masaru, Watanabe Kenji.

    Medicine (Medicine (United States))  102 ( 48 ) e36191 2023.12

    Research paper (scientific journal), Accepted,  ISSN  0025-7974

     View Summary

    Two representative Kampo formulas, keishibukuryogan and tokishakuyakusan, are frequently prescribed for patients with dysmenorrhea. We previously constructed a model that could predict which of these 2 formulas was most suitable, which is based on 4 subjective symptoms and 3 objective signs. To evaluate the prognosis of patients with dysmenorrhea using the established prediction model and assess the treatment outcomes between those treated in accordance with the prediction model and those who received various other treatments. In this retrospective, observational study, we included patients with menstrual pain who visited the Kampo Clinic at the Keio University Hospital for the first time between October 2014 and December 2020. These patients were monitored over a 90-day follow-up period. Participants were categorized into 2 groups: model-accordance and various-options. The progression of visual analogue scale (VAS) values was evaluated by determining the slopes from regression analysis between these 2 groups, with changes corroborated by the medical records. The study comprised 57 patients: 37 in the model-accordance group and 20 in the various-options group. Notably, the various-options group reported a significantly higher number of subjective symptoms (P = .03). The VAS value showed a decline, as indicated by the negative slope value of the regression line, across both groups - irrespective of their classification. There were no significant differences in the occurrence of adverse events between the 2 groups. The prognosis of patients with dysmenorrhea and the incidence of adverse events remained consistent, regardless of whether the treatment approach was in accordance with the prediction model or varied. Further studies are warranted to assess the prognosis when Kampo formulas are chosen based on the prediction model in the various-options population.

  • Pharmacokinetics/pharmacodynamics analysis and establishment of optimal dosing regimens using unbound cefmetazole concentration for patients infected with Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E).

    Takaya Namiki, Yuta Yokoyama, Hideki Hashi, Rentaro Oda, Aya Jibiki, Hitoshi Kawazoe, Kazuaki Matsumoto, Sayo Suzuki, Tomonori Nakamura.

    Pharmacotherapy. (Pharmacotherapy)  Online ahead of print. 2023.11

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  0277-0008

     View Summary

    Study Objective: Establish methods for measuring cefmetazole (CMZ) concentrations conduct a pharmacokinetic/pharmacodynamic (PK/PD) analysis using unbound CMZ concentrations for extended-spectrum β-lactamase producing enterobacterales (ESBL-E) and investigate optimal dosing regimens for not undergoing hemodialysis (non-HD) and undergoing hemodialysis (HD) patients. Design: Prospective observational study. Patients: Included patients treated with CMZ who provided written informed consent and were admitted to the Tokyo Bay Urayasu Ichikawa Medical Center between August 2021 and July 2022. Measurements: Total and Unbound CMZ concentration was measured by high-performance liquid chromatography (HPLC) with solid-phase extraction and ultrafiltration. Setting: Determining the CMZ dosing regimen involved modified creatinine clearance (CLCR) with measured body weight (BW) using the Cockcroft–Gault equation. For non-HD patients, blood samples were collected during at least three points. For patients undergoing HD, 1 g was administered via intravenous infusion, or rapid intravenous injection after HD, or 30 min before the end of HD. Blood samples were collected before HD (pre-HD), and 1 and 3 h after starting HD and post-HD. All blood samples were collected at steady-state. Patient information was collected from electronic medical records. An unbound PK model was constructed for the non-HD patients. A nomogram was constructed using Monte Carlo simulations with a 90% probability of target attainment at 70% free time above the minimum inhibitory concentration (MIC). For the HD patients, a nomogram was used to determine the optimal dosing regimen for each HD schedule. Main Results: CMZ measurement methods were established. A model analysis of unbound PK in 37 non-HD patients incorporated creatinine clearance (CLCR) using the Cockcroft–Gault equation, albumin (ALB) for clearance and body weight (BW) for the volume of distribution. In Monte Carlo simulations, nomograms corresponding to the MIC (known and unknown) were generated for each covariate. Using the nomogram, non-HD patients with an ESBL-E MIC of 8 mg/L, a BW of 60 kg, an ALB of 25 g/L, and a CLCR of 60 mL/min required administration of 2 g every 6 h (1- and 3-h infusions). Unbound PK model parameters were calculated for 7 HD patients, and the optimal dosing regimens following PK/PD were determined for each HD schedule. In HD patients, the regimen after and during HD was established using a treatment that was effective up to an ESBL-E MIC of 4 mg/L. Conclusions: The nomogram for CMZ regimens established by PK/PD analysis of measured CMZ concentrations enables optimal CMZ dosing for ESBL-E-infected patients.

  • What Factors Improve the Evaluation of Achievement at the End of Pharmacy Practice Experiences?

    Ishikawa H, Kawazoe H, Iwata H, Nakamura Y, Jibiki A, Yokoyama Y, Kobayashi N, Suzuki S, Yamaura K, Nakamura T.

    Japanese Journal of Pharmaceutical Health Care and Sciences ((一社)日本医療薬学会)  49 ( 4 ) 173 - 182 2023.04

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  1346-342X

     View Summary

    2021年度の当大学薬学部の5年次生146名を対象に、実務実習事前学習の学業成績を調査し、実務実習における到達度評価の向上に関わる因子を評価した。146名の実務実習事前学習の学業成績は81.2±2.0点、最大値は86.0点、最小値は74.0点であった。平均値で本学が目標とするスコア3に到達していた項目は薬局実習では10項目中6項目、病院実習では11項目中4項目であり、薬局実習よりも病院実習で目標到達率が低かった。なかでも、「処方箋に基づく調剤」のうち「患者情報の把握」はスコア3以上に到達していた実習生が146人中85人(38.2%)と目標到達率の低い項目であった。今回の検討から、代表的8疾患への関わりを増やすことで到達度評価を向上させる可能性が示唆された。すなわち、少数の患者であっても代表的8疾患に幅広く関わりを経験させる目標を優先させた方が実習生の到達度評価が向上することが示された。

  • Ingenol mebutate inhibits the growth of pancreatic cancer cells in vitro via STING with an efficacy comparable to that of clinically used anticancer agents.

    Kikuyama F, Suzuki S, Jibiki A, Yokoyama Y, Kawazoe H, Kitanaka S, Nakamura T

    Journal of natural medicines (Journal of Natural Medicines)  77 ( 2 ) 343 - 351 2023.01

    Research paper (scientific journal), Joint Work, Corresponding author, Accepted,  ISSN  1340-3443

     View Summary

    Pancreatic cancer is associated with a poor prognosis; thus, there is an urgent need to develop new and effective treatments. Ingenol mebutate (IM), which is isolated from the latex of Euphorbia peplus, was recently shown to be effective against pancreatic cancer cell lines; however, its mechanism of action has not been fully elucidated. In this study, we focused on the less drug-sensitive pancreatic cancer cell line Panc-1 and compared IM to commercially available anticancer drugs using cell survival assays. In addition, we aimed to identify novel biomolecules that may be involved in the mechanism of action of IM using RNA sequencing, western blotting, and inhibition assays. The IC50 values after 72 h of exposure to IM and SN-38, drugs to which the Panc-1 cells are most sensitive among the tested anticancer agents, were 43.1 ± 16.8 nM and 165 ± 37 nM, respectively. IM showed a cytostatic effect equal to or greater than that of the clinically used pancreatic cancer therapeutic drugs. RNA sequencing and protein expression analysis revealed that expression of stimulator of interferon genes (STING) increased at low IM concentration, whereas cell viability decreased. Co-exposure of IM and STING inhibitor, H-151, to Panc-1 or MIA PaCa-2 cell lines canceled the growth-inhibitory effects of IM alone. In conclusion, IM may have an efficacy comparable to that of existing pancreatic cancer therapeutic agents on the less drug-sensitive Panc-1 cell line and the immune-related molecule STING plays a role in the mechanism of action of IM.

display all >>

Papers, etc., Registered in KOARA 【 Display / hide

display all >>

Reviews, Commentaries, etc. 【 Display / hide

  • 薬学教育の立場から医療プロフェッショナリズムを考える.

    鈴木 小夜

    YAKUGAKU ZASSHI (日本薬学会)  in press 2024.06

    Article, review, commentary, editorial, etc. (scientific journal), Single Work, Lead author, Last author, Corresponding author

  • 各領域のスペシャリストと考える薬学教育が目指すべきアウトカム.

    武田香陽子,鈴木 小夜

    薬学教育 (日本薬学教育学会)  in press 2024.02

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work, Last author

  • Connecting and Expanding Pharmaceutics (5) Revision of the Model Core Curriculum for Pharmaceutical Education

    Fukui Tsuguya, Mori Kazuhiko, Suzuki Sayo

    Journal of Pharmaceutical Science and Technology, Japan (The Academy of Pharmaceutical Science and Technology, Japan)  84 ( 1 ) 42 - 47 2024.01

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work,  ISSN  03727629

  • 薬学教育が真に目指すべきコアカリの先のアウトカム~各領域のスペシャリストが考える薬学教育~.

    鈴木 小夜,武田香陽子.

    ファルマシア (公益社団法人 日本薬学会)  59 ( 2 )  2023.02

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work, Lead author, Corresponding author,  ISSN  0014-8601

  • 【明日から使える免疫関連有害事象マネジメント 〜免疫チェックポイント阻害薬の看護ケア〜】免疫チェックポイント阻害薬の薬物動態を知る くすりを知ればケアがよくなる 免疫チェックポイント阻害薬の体内動態と有効性/毒性との関係

    鈴木 小夜, 中村 智徳

    がん看護 ((株)南江堂)  27 ( 2 ) 206 - 212 2022.02

    Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media), Lead author, Corresponding author,  ISSN  13420569

     View Summary

    <文献概要>はじめに 免疫チェックポイント阻害薬(ICI)は使用実績も浅く,体内動態への影響要因や有効性や毒性との関連についてはいまだ不明な点も多いが,現時点での各ICIの体内動態の特徴,体内動態や曝露量(血中濃度)と反応性(有効性/毒性)についてまとめた(表1).体内動態および用量-反応曲線(E-R相関)の基本的な考え方については前稿を参照いただきたい.

display all >>

Presentations 【 Display / hide

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide

  • Development of novel treatment approaches for graft-versus-host disease (GVHD) based on the anti-inflammatory properties of traditional medicine.

    2023.04
    -
    2026.03

    Japan Society for the Promotion of Science; Ministry of Education, Culture, Sports, Science and Technology (MEXT), Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Research grant, Principal investigator

     View Summary

    移植片対宿主病(GVHD)は、造血器悪性腫瘍や血液悪性疾患等に対する同種造血幹細胞移植後に発生する最も重篤な合併症であり、その制御は治療成功に不可欠である。申請者はこれまでに和漢薬・桔梗湯がGVHD発症との関連が注目されているマクロファージの生存・増殖・分極化に影響する可能性を見出している。
    本研究では、マクロファージ細胞を用いたin vitro実験、及び急性/慢性GVHDマウスモデルを作製することにより桔梗湯及び抗炎症作用を有する和漢薬によるGVHD抑制効果及び作用機序を明らかにし(in vivo実験)、新規GVHD予防・治療法の開発を目指す。

  • トウダイグサ科植物由来の抗腫瘍活性インゲノール関連化合物の探索とメカニズム研究

    2022.04
    -
    2023.03

    慶應義塾, 2022年度 学事振興資金(個人研究), Research grant, Principal investigator

  • 植物由来インゲノール関連化合物の膵がん細胞増殖抑制メカニズムに関する研究

    2022.04
    -
    2023.03

    慶應義塾, 福澤基金研究補助, Research grant, Principal investigator

  • The sensitivity to anticancer drugs in special population patients: Effect of an increase in blood bile acid concentration and mechanism analysis.

    2020.04
    -
    2023.03

    Japan Society for the Promotion of Science; Ministry of Education, Culture, Sports, Science and Technology (MEXT), Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C) , Research grant, Principal investigator

     View Summary

    個々の患者の薬剤反応性に基づく治療の個別化は、がんの治療成績向上、患者の生活の質向上に不可欠である。本研究では、近年、がん細胞の生存と遺伝子レベルでの関わりが注目されている胆汁酸に着目し、例えば肝機能障害など血液中の胆汁酸が上昇するような病態が、がん細胞の増殖や抗がん剤反応性に与える影響、そのメカニズムについてがん細胞やがん細胞移植動物を用いて検討する。これにより、患者個々の病態に合わせた適切な抗がん剤の選択、効果的かつ安全ながん薬物治療の実現を目的とする。

  • Effect of bile acid with elevated levels in human serum on cancer cell proliferation and sensitivity to anticancer drugs.

    2017.04
    -
    2020.03

    Keio University, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Research grant, Principal investigator

     View Summary

    Recently, many standard-of-care chemotherapy regimens have been established and new approaches to improve the prevention and early detection of cancer have also been developed. However, unfortunately, they leave much to be desired.
    In this study, we focused on the cancer treatments of patients with conditions like cholestasis. As a first step of this study, we mainly used several human cancer cells and deoxycholate (DCA) or chenodeoxycholate (CDCA) which are components in bile acids. We showed that DCA and / or CDCA with concentrations corresponding to elevated serum levels in such as cholestasis or biliary obstruction by tumors enhanced cell proliferation and / or decreased sensitivity to anticancer drugs depending on the kinds of cancer cells and conditions of bile acids exposure.

display all >>

Intellectual Property Rights, etc. 【 Display / hide

  • Method for determining sensitivity to anticancer agent.

    Date applied: PCT/JP2010/069362  2010.10 

    Date issued: EP 2495568 B1  2018.08

    Patent, Joint

  • METHOD FOR DETERMINING SENSITIVITY TO AN ANTICANCER AGENT.

    Date applied: 特願2011-538506  2010.10 

    Date issued: 特許第5548693号  2014.05

    Patent, Joint

  • METHOD FOR DTERMINATION OF SENSITIVITY TO ANTI-CANCER AGENT.

    Date applied: 特願2011-538507  2010.10 

    Date issued: 特許第5548694号  2014.05

    Patent, Joint

  • METHOD FOR DTERMINATION OF SENSITIVITY TO ANTI-CANCER AGENT.

    Date applied: 13/504,985  2010.10 

    Date issued: US 8,765,713 B2  2014.07

    Patent, Joint

  • 谷川原祐介

    Date applied: 201080049197. 8  2010.10 

    Date issued: ZL 2010 8 0049197.8  2016.03

    Patent, Joint

display all >>

Awards 【 Display / hide

  • 第44回日本臨床薬理学会学術総会 優秀発表賞

    並木孝哉, 横山雄太, 枦 秀樹, 織田錬太郎, 地引綾, 河添 仁, 松元 一明, 鈴木小夜, 中村 智徳., 2023.12, 日本臨床薬理学会

    Type of Award: Award from Japanese society, conference, symposium, etc.

  • 第8回日本薬学教育学会大会 優秀発表賞

    牧山大輝, 松野 昂樹, 小林聡太, 野々宮菜彌, 地引 綾, 横山雄太, 河添仁,津田壮一郎, 大谷壽一, 中村智徳, 鈴木小夜, 2023.08, 日本薬学教育学会, フィードバックと省察ワークシートによる介入が病院実務実習生のプロフェッショナリズム評価と省察能力に与えた影響

    Type of Award: Award from Japanese society, conference, symposium, etc.

  • 第16回日本性差医学・医療学会学術集会優秀演題賞

    地引綾, 村上紗恵子, 吉野鉄大, 堀場裕子, 横山雄太, 河添仁, 鈴木小夜, 渡辺賢治, 中村智徳., 2023.02, 日本性差医学・医療学会, 更年期症状に対する漢方治療不応例の分析

    Type of Award: Award from Japanese society, conference, symposium, etc.

  • 第32回日本医療薬学会年会 Young Investigator's Award(社会人部門)

    並木孝哉, 横山雄太, 枦 秀樹, 地引 綾, 河添 仁, 松元一明, 鈴木小夜, 中村智徳, 2022.09, 第32回日本医療薬学会年会, ESBL産生腸内細菌科細菌に対する血液透析患者の遊離形CMZ濃度を用いたPK/PDに基づく最適投与法の評価.

    Type of Award: Award from Japanese society, conference, symposium, etc.

  • 第3回和漢医薬学会若手研究者フォーラム 優秀発表賞

    仲道公輔, 地引 綾, 横山雄太, 河添 仁, 鈴木小夜, 吉野鉄大, 渡辺賢治, 秋山雅博, 金 倫基, 中村智徳, 2022.08, 第3回和漢医薬学会若手研究者フォーラム, 抗肥満作用を有する漢方薬の薬効と 腸内細菌叢構成の関連性の検討.

    Type of Award: Award from Japanese society, conference, symposium, etc.

display all >>

 

Courses Taught 【 Display / hide

  • ETHICS FOR HEALTHCARE PROFESSIONALS

    2023

  • EARLY EXPOSURE TO HOSPITAL & COMMUNITY PHARMACY

    2023

  • CLINICAL PHARMACY AND PHARMACOTHERAPY

    2023

  • CASE STUDY PRACTICE

    2023

  • ADVANCED PRACTICAL TRAINING IN A HOSPITAL (ABROAD)

    2023

display all >>

Educational Activities and Special Notes 【 Display / hide

  • 新スタンダード薬学シリーズ 第2巻 社会と薬学(東京化学同人).「第1章 1・4・1 プロフェッショナルとは」

    2024.03
    -
    Present

    , Development of Textbook and Teaching Material

  • 第13回日本薬剤師レジデントフォーラム.教育講演「薬剤師のプロフェショナリズムに思うこと(仮)」

    2024.03

    , Lecture at Education Method and Practice

  • 令和5年度 同志社女子大学薬学部 FD「薬学教育におけるプロフェッショナリズム(仮)」

    2023.09

    , Lecture at Education Method and Practice

  • 令和5年度 横浜市立大学医学部 医学科・看護学科合同FD「薬学教育における プロフェッショナリズム」

    2023.08

    , Lecture at Education Method and Practice

  • 症例で学ぶ疫学・生物統計学 : 臨床研究入門(翻訳)(原著名:Epidemiology and Biostatistics. An Introduction to Clinical Research, Second Edition)

    2023.06

    , Development of Textbook and Teaching Material

display all >>

 

Social Activities 【 Display / hide

  • 第2回公開シンポジウム「地域における効果的な薬剤師確保の取組に関する調査研究」令和4年度厚生労働行政推進調査事業補助金(医薬品・医療機器等レギュラトリーサイエンス政策研究事業)

    2023.03
  • 「新薬紹介」日本薬剤師会雑誌

    公益社団法人 日本薬剤師会

    2021.06
    -
    Present
  • University of Southern California Marshall School of Business GSBA 580 C – PRIME Japan 2019 Japanese Women in Business

    University of Southern California Marshall School of Business

    2019.05
  • The Annual Overseas Pharmacy Internship Presentation on February 2nd, 2019

    2019.01
  • University of Southern California Marshall School of Business GSBA 580 C – PRIME Japan 2018 Japanese Women in Business

    University of Southern California Marshall School of Business

    2018.05

display all >>

Media Coverage 【 Display / hide

  • 「各領域の専門家が社会貢献から薬学教育を考える」(日本薬学会第143年会特集号)薬事日報

    薬事日報, 2023.03

  • 「ルーブリック評価,薬局・病院実習でトライアル実施 日本薬学教育学会大会で報告」薬事日報.

    薬事日報 (2017年9月6日(水)第11917号(1面)) , 2017.09

  • 将来を考えるお仕事ガイド-医療に関わるお仕事「薬剤師」.

    Z-KAI, Azest, 2014.02

  • 抗癌剤の反応性判別でバイオマーカー探索‐ヤクルトと慶大が共同研究

    ヤクルト本社、慶應義塾大学, プレスリリース, 2009.04

  • 「大腸がん、薬の効き目予測、タンパク質、量で個人差」日本経済新聞.

    日本経済新聞 (朝刊(取材・新聞掲載)) , 2009.03

display all >>

Academic Activities 【 Display / hide

  • 博士取得者および大学院生を対象としたキャリアデザインワークショップ

    日本薬学会 薬学教育委員会, 

    2023.11

  • 第1回シン・全国学生ワークショップ「薬学の未来を担う学生のためのキャリアデザインワークショップ~博士を取得した先輩と一緒に薬学の未来を考えよう~(仮)」

    日本薬学会 薬学教育委員会, 

    2023.08

  • 日本医療薬学会 第3回臨床教育セミナー「観察研究を始めてみよう」(実行委員)

    2023.04

  • 日本薬学会第143年会「シンポジウム:各領域の専門家が社会貢献から薬学教育を考える」(オーガナイザー・座長)

    (札幌) , 

    2023.03

  • 日本学術会議・公開シンポジウム「薬剤師のプロフェッショナリズムを考える」シンポジスト

    日本学術会議、日本薬学会、日本医療薬学会, 

    2023.01

display all >>

Memberships in Academic Societies 【 Display / hide

  • American Association of Cancer Research, 

    2006
    -
    Present
  • International Association of Therapeutic Drug Monitoring and Clinical Toxicology, 

    2016
    -
    Present
  • Asian Association of School of Pharmacy, 

    2021.01
    -
    Present
  • Japanese Cancer Association, 

    2005
    -
    Present
  • Japan Society of Clinical Oncology, 

    2017
    -
    Present

display all >>

Committee Experiences 【 Display / hide

  • 2023.04
    -
    Present

    日本薬学会薬学教育委員会 委員, 公益社団法人 日本薬学会

  • 2022.04
    -
    Present

    薬学臨床系教員連絡会 関東地区世話人, 薬学臨床系教員連絡会

  • 2021.06
    -
    Present

    日本薬剤師会 薬価基準検討会委員会(幹事), 公益社団法人 日本薬剤師会

  • 2021.02
    -
    Present

    日本薬学会 代議員, 公益社団法人 日本薬学会

  • 2021.02
    -
    Present

    日本薬学会 関東支部幹事, 公益社団法人 日本薬学会

display all >>